Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Basel Medical (BMGL) Cash & Equivalents: 2023-2025

Historic Cash & Equivalents for Basel Medical (BMGL) over the last 3 years, with Q2 2025 value amounting to $2.3 million.

  • Basel Medical's Cash & Equivalents rose 6242.07% to $2.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.3 million, marking a year-over-year increase of 6242.07%. This contributed to the annual value of $2.3 million for FY2025, which is 6182.24% up from last year.
  • According to the latest figures from Q4 2024, Basel Medical's Revenue - Interest and Investment Income is -$146055.0, which was up 3096.0% from -$211551.4 recorded in Q4 2023.
  • In the past 5 years, Basel Medical's Cash & Equivalents ranged from a high of $5.4 million in Q4 2024 and a low of $901754.5 during Q4 2023
  • For the 3-year period, Basel Medical's Cash & Equivalents averaged around $2.5 million, with its median value being $1.9 million (2025).
  • Data for Basel Medical's Revenue - Interest and Investment Income shows a peak YoY increase of 3096.0% (in 2024) and a maximum YoY decrease of 3096.0% (in 2024) over the last 5 years.
  • Basel Medical's Cash & Equivalents (Quarter) stood at $901754.5 in 2023, then surged by 504.36% to $5.4 million in 2024, then plummeted by 57.02% to $2.3 million in 2025.
  • Its Cash & Equivalents was $2.3 million in Q2 2025, compared to $5.4 million in Q4 2024 and $1.4 million in Q2 2024.